Verrica Pharmaceuticals Inc logo

VRCA - Verrica Pharmaceuticals Inc Share Price

$14.59 -0.6  -3.8%

Last Trade - 7:28pm

Sector
Healthcare
Size
Small Cap
Market Cap £277.3m
Enterprise Value £251.2m
Revenue £n/a
Position in Universe 3747th / 6713
Bullish
Bearish
Unlock VRCA Revenue
Momentum
Relative Strength (%)
1m +21.8%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -10.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 9.38
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, VerricaPharmaceuticals Inc revenues was not reported. Net lossincreased 44% to $29.7M. Higher net loss reflects Generaland administrative - Balancing v increase of 39% to $11.8M(expense), Research and development - Balancing valincrease of 17% to $12.9M (expense), Interest incomedecrease of 69% to $473K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

VRCA Revenue Unlock VRCA Revenue

Net Income

VRCA Net Income Unlock VRCA Revenue

Normalised EPS

VRCA Normalised EPS Unlock VRCA Revenue

PE Ratio Range

VRCA PE Ratio Range Unlock VRCA Revenue

Dividend Yield Range

VRCA Dividend Yield Range Unlock VRCA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
VRCA EPS Forecasts Unlock VRCA Revenue
Profile Summary

Verrica Pharmaceuticals Inc. is a United States-based clinical-stage medical dermatology company. The Company is focused on identifying, developing and commercializing pharmaceutical products for the treatment of skin diseases with unmet needs. Its lead product candidate, VP-102, is a drug-device combination of topical solution of cantharidin. The Company also intends to develop second cantharidin-based product candidate, VP-103, for the treatment of plantar warts. The Company has completed one Phase II clinical trial of topical solution of cantharidin administered with the wooden stick part of a cotton-tipped swab. It also conducting another Phase II clinical trial of topical solution of cantharidin administered through applicator, which collectively refer to as VP-102, for the treatment of molluscum.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated July 3, 2013
Public Since June 15, 2018
No. of Shareholders: 37
No. of Employees: 17
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 25,865,542
Free Float (0.0%)
Eligible for
ISAs
SIPPs
VRCA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for VRCA
Upcoming Events for VRCA
Frequently Asked Questions for Verrica Pharmaceuticals Inc
What is the Verrica Pharmaceuticals Inc share price?

As of 7:28pm, shares in Verrica Pharmaceuticals Inc are trading at $14.59, giving the company a market capitalisation of £277.3m. This share price information is delayed by 15 minutes.

How has the Verrica Pharmaceuticals Inc share price performed this year?

Shares in Verrica Pharmaceuticals Inc are currently trading at $14.59 and the price has moved by 17.98% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Verrica Pharmaceuticals Inc price has moved by -5.28% over the past year.

What are the analyst and broker recommendations for Verrica Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Verrica Pharmaceuticals Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Verrica Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Verrica Pharmaceuticals Inc next release its financial results?

Verrica Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Verrica Pharmaceuticals Inc dividend yield?

Verrica Pharmaceuticals Inc does not currently pay a dividend.

Does Verrica Pharmaceuticals Inc pay a dividend?

Verrica Pharmaceuticals Inc does not currently pay a dividend.

When does Verrica Pharmaceuticals Inc next pay dividends?

Verrica Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Verrica Pharmaceuticals Inc shares?

To buy shares in Verrica Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Verrica Pharmaceuticals Inc?

Shares in Verrica Pharmaceuticals Inc are currently trading at $14.59, giving the company a market capitalisation of £277.3m.

Where are Verrica Pharmaceuticals Inc shares listed? Where are Verrica Pharmaceuticals Inc shares listed?

Here are the trading details for Verrica Pharmaceuticals Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: VRCA
What kind of share is Verrica Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Verrica Pharmaceuticals Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Verrica Pharmaceuticals Inc share price forecast 2021?

Shares in Verrica Pharmaceuticals Inc are currently priced at $14.59. At that level they are trading at 31.93% discount to the analyst consensus target price of 0.00.

Analysts covering Verrica Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.518 for the next financial year.

How can I tell whether the Verrica Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Verrica Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been 54.13%. At the current price of $14.59, shares in Verrica Pharmaceuticals Inc are trading at 50.51% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Verrica Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Verrica Pharmaceuticals Inc.

Who are the key directors of Verrica Pharmaceuticals Inc?

Verrica Pharmaceuticals Inc's management team is headed by:

Ted White - PRE
Joe Bonaccorso - OTH
Patrick Burnett - OTH
Paul Manning - CHM
Sean Stalfort - DRC
Mark Prygocki - IND
Gary Goldenberg - OTH
Craig Ballaron - IND
Brian Davis - CFO
Christopher Hayes - GCN
Diem Nguyen - DRC
Lawrence Eichenfield - DRC
Bradley Catalone - OTH
Who are the major shareholders of Verrica Pharmaceuticals Inc?

Here are the top five shareholders of Verrica Pharmaceuticals Inc based on the size of their shareholding:

Manning (Paul B.) Individual Investor
Percentage owned: 37.36% (9.66m shares)
Perceptive Advisors LLC Private Equity
Percentage owned: 13.19% (3.41m shares)
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund
Percentage owned: 5.72% (1.48m shares)
Davidson (Matthew) Individual Investor
Percentage owned: 5.59% (1.45m shares)
Kornitzer Capital Management Inc. Investment Advisor
Percentage owned: 2.57% (666k shares)
Similar to VRCA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.